Prescribing and switching patterns of biologic therapy in patients with psoriasis: real-world experience
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llaf496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Chai Har Loo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Pulau Pinang, Georgetown, Penang, Malaysia. Hauptthemen laut MEDLINE: Psoriasis, Drug Substitution, Biological Products, Practice Patterns, Physicians'. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
The advent of new biologic agents in recent years has increased treatment options for patients with psoriasis.
Objectives
To evaluate the prescribing and switching patterns of biologic agents used for psoriasis in Malaysia.
Methods
Data were obtained from the Malaysian Psoriasis Registry from January 2011 to September 2022. All patients treated with biologic agents were included. Those with at least two entries were selected for subgroup analysis to evaluate switching patterns. ‘Continuous therapy’ was defined as those who continued with the same biologic in the subsequent follow-up, whereas those who switched to another type of biologic were defined as ‘switching therapy’.
Results
Of 25 468 patients, 555 (2.2%) received at least 1 biologic agent. The mean age of patients on biologics was 42.6 years, with a male-to-female ratio of 1 : 0.8. Of 645 biologic prescriptions, secukinumab was the most common (37.8%), followed by ustekinumab (27.9%), adalimumab (18.3%) and guselkumab (4.5%). Etanercept had the longest mean usage duration at 46.2 months. Eighty patients (14.4%) had their biologic agent switched. The most frequent switch pattern was from anti-interleukin (IL)-12/23 to anti-IL-17 (20 of 80, 25%), followed by tumour necrosis factor inhibitors to either anti-IL-17 (13 of 80, 16%) or anti-12/23 (11 of 80, 14%). Anti-IL-17 was the preferred agent on switching (37 of 80, 46%). Primary and secondary lack of efficacy were the most common reasons for switching (46% and 25%, respectively). Concurrent systemic therapy was reported in 21.6% of cases (120 of 555). Of these, 76.6% (92 of 120) had received methotrexate.
Conclusions
Up to 2% of the patients with psoriasis received treatment with biologics. Anti-IL-17 was the preferred first- and second-line biologic agent used in Malaysia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Pulau Pinang, Georgetown, Penang, Malaysia.
- Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
- Department of Dermatology, Sarawak General, Kuching, Sarawak, Malaysia.
ORCID-Profile: Chai Har Loo
Zitieren
APA
Loo, C. H., Thevarajah, S., Tang, M. M., & Robinson, S. (2026). Prescribing and switching patterns of biologic therapy in patients with psoriasis: real-world experience. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf496
Vancouver
Loo CH, Thevarajah S, Tang MM, Robinson S. Prescribing and switching patterns of biologic therapy in patients with psoriasis: real-world experience. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llaf496
BibTeX
@article{Loo2026,
author = {Loo, Chai Har and Thevarajah, Suganthi and Tang, Min Moon and Robinson, Suganthy},
title = {Prescribing and switching patterns of biologic therapy in patients with psoriasis: real-world experience},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llaf496}
}
EUVIMED